2型糖尿病骨质疏松的治疗研究
A Study of the Treatment of Osteoporosis in Type 2 Diabetes Mellitus
DOI: 10.12677/acm.2024.1472035, PDF,    科研立项经费支持
作者: 郑靖威, 周欣雨, 李 科, 荣 誉：西安市常见老龄疾病防治重点实验室、慢病防治研究与转化中心、基础与转化医学研究所，西安医学院，陕西 西安 ；李雪萍*：西安市常见老龄疾病防治重点实验室、慢病防治研究与转化中心、基础与转化医学研究所，西安医学院，陕西 西安 ；西安医学院临床医学院，陕西 西安；宋 梅, 周 韵：西安医学院临床医学院，陕西 西安；郭 剑：陕西省人民医院，陕西 西安
关键词: 2型糖尿病；骨质疏松；降糖药物；抗骨质疏松药物；骨折风险；Type 2 Diabetes Mellitus； Osteoporosis； Hypoglycemic Drugs； Anti-Osteoporotic Drugs； Fracture Risk
摘要: 目前，2型糖尿病(T2DM)、骨质疏松症都是常见的慢性疾病，随着年龄的增加，发病率也会不断升高。T2DM与骨质疏松之间关系密切，T2DM会导致骨质疏松的风险增加，需尽早干预。本文旨在回顾T2DM患者骨质疏松和骨折风险的相关研究，分别讨论降糖药物对骨代谢及抗骨质疏松药物对血糖的影响，以及对骨质疏松的现有治疗方案加以总结，以期为该病的治疗及相关研究提供参考，并为最佳治疗提供个性化指导。
Abstract: Currently, type 2 diabetes mellitus (T2DM) and osteoporosis are common chronic diseases with increasing prevalence with age. There is a close relationship between T2DM and osteoporosis, and T2DM leads to an increased risk of osteoporosis and requires early intervention. The purpose of this article is to review the studies related to osteoporosis and fracture risk in patients with T2DM, to discuss the effects of glucose-lowering drugs on bone metabolism and anti-osteoporosis drugs on blood glucose, respectively, as well as to summarize the existing treatment options for osteoporosis, with the aim of providing a reference to the treatment of this disease and related studies, and to provide personalized guidance for the optimal treatment.
文章引用：郑靖威, 周欣雨, 李雪萍, 宋梅, 郭剑, 周韵, 李科, 荣誉. 2型糖尿病骨质疏松的治疗研究[J]. 临床医学进展, 2024, 14(7): 450-459. https://doi.org/10.12677/acm.2024.1472035

参考文献

[1] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
[2] Zhang, L., Long, J., Jiang, W., Shi, Y., He, X., Zhou, Z., et al. (2016) Trends in Chronic Kidney Disease in China. New England Journal of Medicine, 375, 905-906. [Google Scholar] [CrossRef] [PubMed]
[3] Papatheodorou, K., Papanas, N., Banach, M., Papazoglou, D. and Edmonds, M. (2016) Complications of Diabetes 2016. Journal of Diabetes Research, 2016, Article ID: 6989453. [Google Scholar] [CrossRef] [PubMed]
[4] Janghorbani, M., Van Dam, R.M., Willett, W.C. and Hu, F.B. (2007) Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture. American Journal of Epidemiology, 166, 495-505. [Google Scholar] [CrossRef] [PubMed]
[5] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022) [J]. 中国全科医学, 2022, 26(14): 1671-1691.
[6] Mohsin, S., Baniyas, M.M., AlDarmaki, R.S., Tekes, K., Kalász, H. and Adeghate, E.A. (2019) An Update on Therapies for the Treatment of Diabetes-Induced Osteoporosis. Expert Opinion on Biological Therapy, 19, 937-948. [Google Scholar] [CrossRef] [PubMed]
[7] Jackuliak, P. and Payer, J. (2014) Osteoporosis, Fractures, and Diabetes. International Journal of Endocrinology, 2014, Article ID: 820615. [Google Scholar] [CrossRef] [PubMed]
[8] Neglia, C., Argentiero, A., Chitano, G., Agnello, N., Ciccarese, R., Vigilanza, A., et al. (2016) Diabetes and Obesity as Independent Risk Factors for Osteoporosis: Updated Results from the ROIS/EMEROS Registry in a Population of Five Thousand Post-Menopausal Women Living in a Region Characterized by Heavy Environmental Pressure. International Journal of Environmental Research and Public Health, 13, Article No. 1067. [Google Scholar] [CrossRef] [PubMed]
[9] Napoli, N., Chandran, M., Pierroz, D.D., Abrahamsen, B., Schwartz, A.V. and Ferrari, S.L. (2016) Mechanisms of Diabetes Mellitus-Induced Bone Fragility. Nature Reviews Endocrinology, 13, 208-219. [Google Scholar] [CrossRef] [PubMed]
[10] Majumdar, S.R., Leslie, W.D., Lix, L.M., Morin, S.N., Johansson, H., Oden, A., et al. (2016) Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. The Journal of Clinical Endocrinology & Metabolism, 101, 4489-4496. [Google Scholar] [CrossRef] [PubMed]
[11] Aung, M., Amin, S., Gulraiz, A., Gandhi, F.R., Pena Escobar, J.A. and Malik, B.H. (2020) The Future of Metformin in the Prevention of Diabetes-Related Osteoporosis. Cureus, 12, e10412. [Google Scholar] [CrossRef] [PubMed]
[12] Vestergaard, P., Rejnmark, L. and Mosekilde, L. (2005) Relative Fracture Risk in Patients with Diabetes Mellitus, and the Impact of Insulin and Oral Antidiabetic Medication on Relative Fracture Risk. Diabetologia, 48, 1292-1299. [Google Scholar] [CrossRef] [PubMed]
[13] Oei, L., Zillikens, M.C., Dehghan, A., Buitendijk, G.H.S., Castaño-Betancourt, M.C., Estrada, K., et al. (2013) High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 36, 1619-1628. [Google Scholar] [CrossRef] [PubMed]
[14] Ma, P., Gu, B., Ma, J., E, L., Wu, X., Cao, J., et al. (2010) Glimepiride Induces Proliferation and Differentiation of Rat Osteoblasts via the PI3-Kinase/Akt Pathway. Metabolism, 59, 359-366. [Google Scholar] [CrossRef] [PubMed]
[15] Abe, H., Shikuma, J., Suwanai, H., Sano, K., Okumura, T., Kan, K., et al. (2019) Assessing Hypoglycemia Frequency Using Flash Glucose Monitoring in Older Japanese Patients with Type 2 Diabetes Receiving Oral Hypoglycemic Agents. Geriatrics & Gerontology International, 19, 1030-1035. [Google Scholar] [CrossRef] [PubMed]
[16] Kalaitzoglou, E., Fowlkes, J.L., Popescu, I. and Thrailkill, K.M. (2018) Diabetes Pharmacotherapy and Effects on the Musculoskeletal System. Diabetes/Metabolism Research and Reviews, 35, e3100. [Google Scholar] [CrossRef] [PubMed]
[17] Paschou, S.Α., Dede, A.D., Anagnostis, P.G., Vryonidou, A., Morganstein, D. and Goulis, D.G. (2017) Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. The Journal of Clinical Endocrinology & Metabolism, 102, 3621-3634. [Google Scholar] [CrossRef] [PubMed]
[18] Benvenuti, S., Cellai, I., Luciani, P., Deledda, C., Baglioni, S., Giuliani, C., et al. (2007) Rosiglitazone Stimulates Adipogenesis and Decreases Osteoblastogenesis in Human Mesenchymal Stem Cells. Journal of Endocrinological Investigation, 30, RC26-RC30. [Google Scholar] [CrossRef] [PubMed]
[19] Shockley, K.R., Lazarenko, O.P., Czernik, P.J., Rosen, C.J., Churchill, G.A. and Lecka‐Czernik, B. (2008) Pparγ2 Nuclear Receptor Controls Multiple Regulatory Pathways of Osteoblast Differentiation from Marrow Mesenchymal Stem Cells. Journal of Cellular Biochemistry, 106, 232-246. [Google Scholar] [CrossRef] [PubMed]
[20] Schwartz, A.V. and Sellmeyer, D.E. (2007) Thiazolidinediones: New Evidence of Bone Loss. The Journal of Clinical Endocrinology & Metabolism, 92, 1232-1234. [Google Scholar] [CrossRef] [PubMed]
[21] Zhu, Z., Jiang, Y. and Ding, T. (2014) Risk of Fracture with Thiazolidinediones: An Updated Meta-Analysis of Randomized Clinical Trials. Bone, 68, 115-123. [Google Scholar] [CrossRef] [PubMed]
[22] Huang, L., Zhong, W., Liang, X., Wang, H., Fu, S. and Luo, Z. (2024) Meta-Analysis on the Association between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis. Journal of Clinical Densitometry, 27, Article ID: 101455. [Google Scholar] [CrossRef] [PubMed]
[23] Paschou, S.Α., Anagnostis, P., Pavlou, D.I., Vryonidou, A., Goulis, D.G. and Lambrinoudaki, I. (2019) Diabetes in Menopause: Risks and Management. Current Vascular Pharmacology, 17, 556-563. [Google Scholar] [CrossRef] [PubMed]
[24] Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., et al. (2014) SGLT2 Inhibitor Lowers Serum Uric Acid through Alteration of Uric Acid Transport Activity in Renal Tubule by Increased Glycosuria. Biopharmaceutics & Drug Disposition, 35, 391-404. [Google Scholar] [CrossRef] [PubMed]
[25] Koike, Y., Shirabe, S., Maeda, H., Yoshimoto, A., Arai, K., Kumakura, A., et al. (2019) Effect of Canagliflozin on the Overall Clinical State Including Insulin Resistance in Japanese Patients with Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice, 149, 140-146. [Google Scholar] [CrossRef] [PubMed]
[26] Lupsa, B.C. and Inzucchi, S.E. (2018) Use of SGLT2 Inhibitors in Type 2 Diabetes: Weighing the Risks and Benefits. Diabetologia, 61, 2118-2125. [Google Scholar] [CrossRef] [PubMed]
[27] Watts, N.B., Bilezikian, J.P., Usiskin, K., Edwards, R., Desai, M., Law, G., et al. (2016) Effects of Canagliflozin on Fracture Risk in Patients with Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 101, 157-166. [Google Scholar] [CrossRef] [PubMed]
[28] Lu, N., Sun, H., Yu, J., Wang, X., Liu, D., Zhao, L., et al. (2015) Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Has Anabolic Bone Effects in Ovariectomized Rats without Diabetes. PLOS ONE, 10, e0132744. [Google Scholar] [CrossRef] [PubMed]
[29] Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., et al. (2007) The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption. Endocrinology, 149, 574-579. [Google Scholar] [CrossRef] [PubMed]
[30] Cai, T., Li, H., Jiang, L., Wang, H., Luo, M., Su, X., et al. (2021) Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study. BioMed Research International, 2021, Article ID: 3361309. [Google Scholar] [CrossRef] [PubMed]
[31] Cheng, L., Hu, Y., Li, Y., Cao, X., Bai, N., Lu, T., et al. (2019) Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Bone Fracture in Patients with Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials. Diabetes/Metabolism Research and Reviews, 35, e3168. [Google Scholar] [CrossRef] [PubMed]
[32] 张岩松, 王可可, 刘力嘉, 等. GLP-1受体激动剂对2型糖尿病患者骨折风险影响的Meta分析[J]. 中国骨质疏松杂志, 2018, 24(7): 847-855.
[33] Yang, J., Zhang, X., Wang, W. and Liu, J. (2010) Insulin Stimulates Osteoblast Proliferation and Differentiation through ERK and PI3K in MG‐63 Cells. Cell Biochemistry and Function, 28, 334-341. [Google Scholar] [CrossRef] [PubMed]
[34] Cornish, J., Callon, K.E. and Reid, I.R. (1996) Insulin Increases Histomorphometric Indices of Bone Formation in Vivo. Calcified Tissue International, 59, 492-495. [Google Scholar] [CrossRef] [PubMed]
[35] Clemens, T.L. and Karsenty, G. (2010) The Osteoblast: An Insulin Target Cell Controlling Glucose Homeostasis. Journal of Bone and Mineral Research, 26, 677-680. [Google Scholar] [CrossRef] [PubMed]
[36] Thrailkill, K.M., Lumpkin, C.K., Bunn, R.C., Kemp, S.F. and Fowlkes, J.L. (2005) Is Insulin an Anabolic Agent in Bone? Dissecting the Diabetic Bone for Clues. American Journal of Physiology-Endocrinology and Metabolism, 289, E735-E745. [Google Scholar] [CrossRef] [PubMed]
[37] Dutta, M., Pakhetra, R. and Garg, M. (2012) Evaluation of Bone Mineral Density in Type 2 Diabetes Mellitus Patients before and after Treatment. Medical Journal Armed Forces India, 68, 48-52. [Google Scholar] [CrossRef] [PubMed]
[38] Schwartz, A.V., Hillier, T.A., Sellmeyer, D.E., Resnick, H.E., Gregg, E., Ensrud, K.E., et al. (2002) Older Women with Diabetes Have a Higher Risk of Falls. Diabetes Care, 25, 1749-1754. [Google Scholar] [CrossRef] [PubMed]
[39] Ivers, R.Q., Cumming, R.G., Mitchell, P. and Peduto, A.J. (2001) Diabetes and Risk of Fracture: The Blue Mountains Eye Study. Diabetes Care, 24, 1198-1203. [Google Scholar] [CrossRef] [PubMed]
[40] Cremers, S. and Papapoulos, S. (2011) Pharmacology of Bisphosphonates. Bone, 49, 42-49. [Google Scholar] [CrossRef] [PubMed]
[41] Vestergaard, P., Rejnmark, L. and Mosekilde, L. (2010) Are Antiresorptive Drugs Effective against Fractures in Patients with Diabetes? Calcified Tissue International, 88, 209-214. [Google Scholar] [CrossRef] [PubMed]
[42] Eastell, R., Vittinghoff, E., Lui, L., Ewing, S.K., Schwartz, A.V., Bauer, D.C., et al. (2020) Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk. Journal of Bone and Mineral Research, 37, 2121-2131. [Google Scholar] [CrossRef] [PubMed]
[43] Keegan, T.H.M., Schwartz, A.V., Bauer, D.C., Sellmeyer, D.E. and Kelsey, J.L. (2004) Effect of Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Type 2 Diabetic Women. Diabetes Care, 27, 1547-1553. [Google Scholar] [CrossRef] [PubMed]
[44] Schwartz, A., Vittinghof, E., Bauer, D.C., Cummings, S.R., Grey, A., McClung, M.R. and Black, D.M. (2015) Bisphosphonates Reduce Fracture Risk in Postmenopausal Women with Diabetes: Results from FIT and HORIZON Trials. American Society for Bone and Mineral Research.
[45] Karimi Fard, M., Aminorroaya, A., Kachuei, A., Salamat, M.R., Hadi Alijanvand, M., Aminorroaya Yamini, S., et al. (2018) Alendronate Improves Fasting Plasma Glucose and Insulin Sensitivity, and Decreases Insulin Resistance in Prediabetic Osteopenic Postmenopausal Women: A Randomized Triple‐Blind Clinical Trial. Journal of Diabetes Investigation, 10, 731-737. [Google Scholar] [CrossRef] [PubMed]
[46] Cummings, S.R., Martin, J.S., McClung, M.R., Siris, E.S., Eastell, R., Reid, I.R., et al. (2009) Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 361, 756-765. [Google Scholar] [CrossRef] [PubMed]
[47] Kiechl, S., Wittmann, J., Giaccari, A., Knoflach, M., Willeit, P., Bozec, A., et al. (2013) Blockade of Receptor Activator of Nuclear Factor-Κb (RANKL) Signaling Improves Hepatic Insulin Resistance and Prevents Development of Diabetes Mellitus. Nature Medicine, 19, 358-363. [Google Scholar] [CrossRef] [PubMed]
[48] Passeri, E., Benedini, S., Costa, E. and Corbetta, S. (2015) A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women. International Journal of Endocrinology, 2015, Article ID: 352858. [Google Scholar] [CrossRef] [PubMed]
[49] Celer, O., Akalın, A. and Oztunali, C. (2016) Effect of Teriparatide Treatment on Endothelial Function, Glucose Metabolism and Inflammation Markers in Patients with Postmenopausal Osteoporosis. Clinical Endocrinology, 85, 556-560. [Google Scholar] [CrossRef] [PubMed]
[50] Karras, S.N., Anagnostis, P., Antonopoulou, V., Tsekmekidou, X., Koufakis, T., Goulis, D.G., et al. (2017) The Combined Effect of Vitamin D and Parathyroid Hormone Concentrations on Glucose Homeostasis in Older Patients with Prediabetes: A Cross-Sectional Study. Diabetes and Vascular Disease Research, 15, 150-153. [Google Scholar] [CrossRef] [PubMed]
[51] Vestergaard Kvist, A., Faruque, J., Vallejo-Yagüe, E., Weiler, S., Winter, E.M. and Burden, A.M. (2021) Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Journal of Clinical Medicine, 10, Article No. 1660. [Google Scholar] [CrossRef] [PubMed]
[52] Feigh, M., Hjuler, S.T., Andreassen, K.V., Gydesen, S., Ottosen, I., Henriksen, J.E., et al. (2014) Oral Salmon Calcitonin Enhances Insulin Action and Glucose Metabolism in Diet-Induced Obese Streptozotocin-Diabetic Rats. European Journal of Pharmacology, 737, 91-96. [Google Scholar] [CrossRef] [PubMed]
[53] Khosla, S. and Hofbauer, L.C. (2017) Osteoporosis Treatment: Recent Developments and Ongoing Challenges. The Lancet Diabetes & Endocrinology, 5, 898-907. [Google Scholar] [CrossRef] [PubMed]
[54] Kanazawa, I. (2017) Interaction between Bone and Glucose Metabolism. Endocrine Journal, 64, 1043-1053. [Google Scholar] [CrossRef] [PubMed]
[55] Dionello, C.F., Sá-Caputo, D., Pereira, H.V.F.S., Sousa-Gonçalves, C.R., Maiworm, A.I., Morel, D.S. and Bernardo-Filho, M. (2016) Effects of Whole Body Vibration Exercises on Bone Mineral Density of Women with Postmenopausal Osteoporosis without Medications: Novel Findings and Literature Review. Journal of Musculoskeletal & Neuronal Interactions, 16, 193-203.
[56] Liu, X., Gao, X., Tong, J., Yu, L., Xu, M. and Zhang, J. (2022) Improvement of Osteoporosis in Rats with Hind-Limb Unloading Treated with Pulsed Electromagnetic Field and Whole-Body Vibration. Physical Therapy, 102, pzac097. [Google Scholar] [CrossRef] [PubMed]

为你推荐